Keywords Melanoma Adjuvant anti-PD1 Immune-related adverse events Immunotherapy Real-world evidence Seasonal variation 1 Introduction Immune checkpoint inhibitors (ICIs) have changed treatment of both advanced melanoma and other cancers dramatically. By enhancing the antitumor immune response, ICIs significantly improve survival and is now a main pillar in melanoma treatment[1–3] 1. Ascierto, P.A. ∙ Del Vecchio, M. ∙ Robert, C. ...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Lars Bastholt
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy
Keywords: vandetanib; multikinase inhibitor; differentiated thyroid cancer; progression-free survival; radioiodine refractory Introduction Differentiated thyroid cancer (DTC), including papillary, follicular, oncocytic carcinoma, and poorly differentiated cancers, arises from aberrant follicular cells of the thyroid and accounts for >90% of all thyroid malignancies (Sherman 2003, Haugen et al. 2016).
PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
Highlights • PD-L1≥1% is an independent positive prognostic biomarker in metastatic melanoma • PD-L1≥1% did not derive additional benefit from anti-CTLA-4 over anti-PD-1 alone • Combination therapy demonstrated improved PFS only in patients with PD-L1<1% Abstract Metastatic melanoma (MM) is commonly treated with a combination of nivolumab and ipilimumab, regardless of tumor PD-L1 expression.
Howick JCI, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. In: Group OLoEW, editor The Oxford levels of evidence 2: Oxford center for evifdence-based medicine https://wwwcebmnet/indexaspx?o=5653 Access Date: 23 April 2019. Eggermont A.M. Spatz A. Robert C. Cutaneous melanoma. Lancet. 2014; 383: 816-827 Garbe C. Peris K. Hauschild A. Saiag P. Middleton M. Spatz A. et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010; 46: 270-283 Garbe C.
Response to: Comment on ‘Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines’
We thank Testori et al. [ 1 Testori A.E. Kunte C. Clover A.J.P. Bechara F.G. Bertino G. Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines”. Eur J Canc. 2020; ] for their letter to the Editor related to our published European consensus-based interdisciplinary guidelines on the diagnosis and treatment of basal cell carcinoma (BCC) [ 2 Peris K. Fargnoli M.C. Garbe C. Kaufmann R. Bastholt L. Seguin N.B. et al.
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
Medullary thyroid cancer (MTC) is a rare neuroendocrine malignancy that derives from parafollicular cells (C cells) of the thyroid gland that secrete the polypeptide hormone calcitonin.1,2 It accounts for almost 5% of all thyroid cancers1,3 and occurs in either a hereditary (25%) or a sporadic (75%) pattern.4,5 The 10-year overall survival rate in unselected patients with MTC is approximately 75%, but it decreases to ≤ 40% in patients with locally advanced or metastatic disease.6 CONTEXT Key...
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019
Abstract A unique collaboration of multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization for Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with 1- to 2-cm safety margins.
High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 (A) Progression-free survival (PFS) and (B) overall survival (OS) for 464 patients treated with HD IL-2/IFN as first-line treatment for metastatic melanoma with a median follow-up time of 6.4 years. HD, high-dose; IFN; interferon; IL-2, interleukin-2. Fig.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Lars
Contact Lars, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack